KRAS and cancer: Our observations show that a reduced nuclear size is specific to oncogenic Kras and not cMyc or Cyclin D1T286A expression in PDAC cells; this may partially explain why cancer types reliant on distinct oncogenic signaling networks have an increase in nuclear size, while others have a decreased nuclear size.